

# **Ji-Won Kim**

Mobile: +82-10-9010-0427

E-mail: [jiwonkim@snuh.org](mailto:jiwonkim@snuh.org)

## **CURRENT POSITION**

Assistant Professor

Division of Hematology and Medical Oncology

Department of Internal Medicine

Seoul National University Bundang Hospital

82 Gumi-ro-173-beon-gil

Bundang-gu, Seongnam 13620 Korea

## **EDUCATION**

**Seoul National University College of Medicine, Seoul, Korea**

Mar. 2014 – Present

**Ph.D. Candidate**, Major: Clinical Medical Sciences

Advisor: Prof. Sung-Soo Yoon

**Kyoto University, Kyoto, Japan**

Jul. 2014

**KSH-JSH Fellowship Exchange Program**

Advisor: Prof. Seishi Ogawa (Department of Pathology and Tumor Biology)

**Seoul National University College of Medicine, Seoul, Korea**

Mar. 2009 – Feb. 2014

**M.S.**, Major: Molecular Oncology

Feb. 2014

Advisor: Prof. Seock-Ah Im

**Seoul National University College of Medicine, Seoul, Korea**

Mar. 1999 – Feb. 2005

**M.D.**, Major: Medicine

Feb. 28, 2005

## **PROFESSIONAL EXPERIENCES**

**Seoul National University Bundang Hospital, Seongnam, Korea**

Mar. 2015 – Present

**Assistant Professor** in Division of Hematology and Medical Oncology

**Seoul National University Hospital, Seoul, Korea**

May 2013 – Feb. 2015

**Clinical Fellow** in Division of Hematology and Medical Oncology

<b>Chuncheon Public Healthcare Center</b> , Chuncheon, Korea	Apr. 2011 – Apr. 2013
<b>Public Health Doctor</b> , an alternative military service for 3 years in Korea	
<b>Yangyang Public Healthcare Center</b> , Yangyang, Korea	Apr. 2010 – Apr. 2011
<b>Public Health Doctor</b> , an alternative military service for 3 years in Korea	
<b>Seoul National University Hospital</b> , Seoul, Korea	Mar. 2006 – Feb. 2010
<b>Resident Physician</b> in Department of Internal Medicine	
<b>Seoul National University Hospital</b> , Seoul, Korea	Mar. 2005 – Feb. 2006
<b>Intern</b>	

## HONORS AND AWARDS

- GSK Award**, Korean Cancer Association Annual Meeting 2014
- Roche Award**, Korean Cancer Association Annual Meeting 2014
- Scholar-in-Training Award (Avon Foundation-AACR International Travel Grant)**, American Association for Cancer Research (AACR) Annual Meeting 2013
- Korea Cancer Foundation Scholarship**, Korea Cancer Foundation, Seoul, Korea Mar. 2013 – Feb. 2014
- Minister's Citation on World Health Day**, Ministry of Health and Welfare, Korea 6, Apr. 2012
- Travel Award**, American Society of Hematology Annual Meeting 2010

## SELECTED PUBLICATIONS

1. Nam AR, **Kim JW (co-first author)**, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Src as a therapeutic target in biliary tract cancer. *Mol Cancer Ther.* 2016 [Epub ahead of print]
2. **Kim JW (first author)**, Kim DK, Min A, Lee KH, Nam HJ, Kim JH, Kim JS, Kim TY, Im SA, Park IA. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. *J Cancer Res Clin Oncol.* 2016 Jan;142(1):157-65.
3. **Kim JW (first author)**, Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. *J Clin Virol.* 2015 Dec;73:64-9.
4. **Kim JW (co-first author)**, Kim SW, Tada K, Fukuda T, Lee JH, Lee JJ, Kwon JH, Bang SM, Kim I, Yoon SS, Lee JS, Park S. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell

lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. *Ann Hematol.* 2014 Aug;93(8):1345-51.

5. **Kim JW (co-first author)**, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, Heo DS, Bang YJ. Clinical implications of VEGF, TGF- $\beta$ 1, and IL-1 $\beta$  in patients with advanced non-small cell lung cancer. *Cancer Res Treat.* 2013 Dec;45(4):325-33.

6. **Kim JW (first author)**, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. *Cancer Chemother Pharmacol.* 2013 Nov;72(5):1023-9.

7. **Kim JW (first author)**, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. *Cancer Chemother Pharmacol.* 2013 Jul;72(1):109-15.

8. Bae JY, **Kim JW (co-first author)**, Kim I. Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. *Oncol Rep.* 2013 Jul;30(1):485-91.

9. Kim KI, **Kim JW (co-first author)**, Lee HJ, Kim BS, Bang SM, Kim I, Oh JM, Yoon SS, Lee JS, Park S, Kim BK. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation. *Am J Hematol.* 2013 Feb;88(2):107-12.

10. **Kim JW (first author)**, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. *Oncology.* 2012;83(4):218-27.

11. **Kim JW (first author)**, Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, Kim I, Yoon SS, Lee JS, Kim CS, Park S, Kim BK. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. *Am J Hematol* 2012 May;87(5):479-83.

12. **Kim JW (first author)**, Kim BS, Bang SM, Kim I, Kim DH, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, Park S, Kim BK; Korean Society of Blood and Marrow Transplantation. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who

experienced relapse or progression after autologous stem cell transplantation. *Ann Hematol.* 2011 Dec;90(12):1409-18.

13. **Kim JW (first author)**, Lee JO, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. *Am J Clin Oncol.* 2011 Apr;34(2):125-9.

14. **Kim JW (first author)**, Kim I, Oh KH, Yoon SS, Oh MD, Song YW, Heo DS, Bang YJ, Han KS, Han JS, Park S, Kim BK. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. *Hematology.* 2011 Mar;16(2):73-9.